Please assess the completion status of the following clinical trial:

Trial Title: A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects 1 to 17 years of age with assent to participation and his/her parent or guardian is willing and able to sign the informed consent approved by the Independent Review Board / Ethics Committee.~* Screening TSAT \< 20%~* Screening Hemoglobin \< 11 g/dL~* For subjects who are receiving an erythropoietin stimulating agent (ESA): stable ESA therapy (+/- 20% of current dose) for \> 8 weeks prior to the qualifying screening visit and no ESA dosing or product changes anticipated for the length of the trial~Exclusion Criteria:~* Known hypersensitivity reaction to any component of Ferric Carboxymaltose.~* Subject previously randomized and treated in this study or any other clinical study of Ferric Carboxymaltose (FCM or VIT-45).~* Body mass index (BMI) ≤ 5th percentile for age (see APPENDIX 2)~* Male or Female subject 1 year of age weighing \< 12kg.~* History of acquired iron overload, hemochromatosis or other iron accumulation disorders.~* Chronic kidney disease subjects on hemodialysis.~* Screening Ferritin level \> 300ng/mL~* Subjects with significant severe diseases of the liver, hemopoietic system, cardiovascular system, psychiatric disorder or other conditions which on the opinion of the investigator may place a subject at added risk.~* Any active infection.~* Known positive hepatitis B antigen (HBsAg) or hepatitis C viral antibody (HCV) with evidence of active hepatitis.~* Known positive HIV-1/HIV-2 antibodies (anti-HIV).~* Anemia due to reasons other than iron deficiency (i.e. hemoglobinopathy). Subjects treated with vitamin B12 or folic acid deficiency are permitted.~* Intravenous iron and /or blood transfusion in the 4 weeks prior to screening.~* Immunosuppressive therapy that may lead to anemia (i.e. cyclophosphamide, azathioprine, mycophenolate mofetil). Note steroid therapy is permitted.~* Administration and / or use of an investigational product (drug or device) within 30 days of screening.~* Alcohol or drug abuse within the past six months.~* Female subjects who are pregnant or lactating, or sexually active female who are of childbearing potential not willing to use an acceptable form of contraceptive precautions during the study.~* Subject is unable to comply with study assessments.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ferric Carboxymaltose (FCM) (Type: EXPERIMENTAL): FCM at 7.5 mg/kg or 15 mg/kg to a maximum single dose of 750 mg iron, whichever is smaller

Based on this trial design, predict the completion outcome and termination type (if applicable).